NewAmsterdam Pharma Company NV has published a document on the effects of obicetrapib, both alone and in combination with ezetimibe, on reverse cholesterol transport and VLDL production in mice. The research demonstrated that obicetrapib and ezetimibe reduce non-HDL-C levels by enhancing VLDL clearance and increasing LDL receptor expression. The study utilized APOE*3-Leiden.CETP mice to evaluate the mechanisms of obicetrapib and ezetimibe in a controlled setting. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.